Logo

AbCellera Enters into a Collaboration Agreement with Prelude Therapeutics to Develop Antibody Drug Conjugated to Treat Cancer

Share this
AbCellera

AbCellera Enters into a Collaboration Agreement with Prelude Therapeutics to Develop Antibody Drug Conjugated to Treat Cancer

Shots:

  • AbCellera granted Prelude the exclusive worldwide rights to jointly discover, develop & commercialize up to 5 ADC programs targeting cancer indications
  • As per agreement, AbCellera was held responsible for all the manufacturing activities & Prelude for the clinical development & global commercialization. Additionally, AbCellera also received the option to co-promote the products in the US
  • The collaboration synergistically uses AbCellera's antibody discovery and development engine to generate precision ADCs with Prelude's targeted protein degradation & medicinal chemistry expertise for the treatment of cancer. The first program will enhance the reach of Prelude’s small molecule SMARCA2 selective degraders

Ref: AbCellera | Image: AbCellera

Related News:- Confo Therapeutics Entered into a Research Collaboration with AbCellera for GPCR-Targeting Antibody Discovery

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions